Agenda will run 8.20am - 6.00pm CET
8:00 am Virtual Coffee Networking Morning
8:20 am Chair’s Opening Remarks
Precision Medicine Application Across an Evolving European Landscape: Exciting Advancements & Current Socio-Political Environment
8:30 am The Translational Perspective: Early Biomarker Decisions Today to Influence Precision Medicine Successes of Tomorrow
Synopsis
- Starting with the end in mind: Early biomarker decisions for down the line precision medicine success and optimise outcomes for patients
- Working with your stakeholders to devise a robust biomarker programme
- Bridging the preclinical and clinical gap, and translating clinically validated predictive biomarkers with improved treatment outcomes
9:00 am Session Reserved for NeoGenomics Laboratories
9:30 am Session Reserved for Roche Tissue Diagnostics
10:00 am Panel Discussion: Current Socio-Political & the Changing Healthcare Landscape Influences on Precision Medicine Delivery in the EU
Synopsis
- Implications of Covid-19 on the delivery of precision medicine
- Following Brexit: How are impacts being felt across the industry and potential disruptions to targeted therapy development
- Precision medicine in the EU: A leading precision medicine market but where can we improve? Highlighting challenges connecting a diverse landscape to deliver better treatment outcomes
- With IVDR regulations coming into effect in just over a year in the EU – Where are we now? What bottlenecks are foreseen for precision medicine implementation come May 2022?
10:45 am Session reserved for HalioDx
11:15 am Speed Networking & Coffee Networking Break
1:15 pm Networking Lunch
Synopsis
Whilst enjoying a bite to eat, you can take part in:
- 121 Pre-Scheduled Meetings With Our Event Partners: Take part in 1:1 networking with market leaders pioneering exciting advances in the biomarker-driven drug development space
- Group Networking: Join your fellow attendees for groups discussions reflecting on the morning’s topics. Collaborate and connect to consider applying new ideas and innovations to propel your pipelines forward
4:00 pm Afternoon Speed Networking Break
4:20 pm Panel Discussion: Women & Diversity in Precision Medicine
Data & Advanced Technology in Rare Disease: Generating Insights for Faster & More Focussed Patient Stratification
Moderator: Guillaume Desachy, Principal Biostatistician, AstraZeneca
5:00 pm Harnessing Transcriptional Profiling for Immune-Based Cancer Patient Stratification
Synopsis
- Deconvolution of bulk gene expression tumour data allows for a comprehensive quantification of a complete set of immune cell fractions within the tumor context
- The quantification of immune cell fractions can contribute to identify those immune cell types which may have a role in patient survival, and therefore contribute to a more precise stratification of patients based on their predicted prognosis
- The use of functional signatures of drug response can also contribute to identify potential therapeutic strategies specific for each one of the identified immune-based groups
5:30 pm An Early Phase Case Study in a Biomarker Selected Patient Subgroup from a Rare Disease
Synopsis
- Talk details coming soon!